- Results from a Phase 3 clinical trial, ECLIPSE, evaluating Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's TREMFYA (guselkumab) compared Novartis' (NVS) COSENTYX (secukinumab) in adult patients with moderate-to-severe plaque psoriasis showed TREMFYA's superiority. The data will be presented at the Inflammatory Skin Disease Summit in Vienna.
- Specifically, 84.5% of patients receiving TREMFYA achieved at least 90% improvement in psoriasis skin surface area (PASI 90) at week 48 versus 70.0% for COSENTYX (p<0.001).
- TREMFYA demonstrated non-inferiority to COSENTYX on the metric of PASI 75 (at least 75% clearance of psoriasis skin area). 84.6% of patients receiving the former achieved the endpoint compared to 80.2% for the latter at week 12 and week 48. Superiority was not demonstrated (p=0.062).
- JNJ is up 1% premarket on light volume.
- Related ticker: (MOR)